This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey
Drugs - Real World Outcomes Open Access 07 October 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fox, J. New law broadens FDA safety authority, renews user fees. Nat Biotechnol 25, 1189–1190 (2007). https://doi.org/10.1038/nbt1107-1189
Issue Date:
DOI: https://doi.org/10.1038/nbt1107-1189
This article is cited by
-
Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey
Drugs - Real World Outcomes (2015)
-
New self-reporting for GM crops
Nature Biotechnology (2011)
-
Trade secrets in balance as agencies issue new transparency rules
Nature Biotechnology (2011)
-
Erythropoietins locked into risk management program
Nature Biotechnology (2010)
-
REMS violations fines
Nature Biotechnology (2009)